Jasper Therapeutics, Inc. (NASDAQ:JSPR) Short Interest Up 13.3% in March

Jasper Therapeutics, Inc. (NASDAQ:JSPRGet Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 327,300 shares, an increase of 13.3% from the February 29th total of 288,900 shares. Approximately 2.8% of the shares of the stock are short sold. Based on an average daily volume of 128,000 shares, the short-interest ratio is presently 2.6 days.

Insider Buying and Selling

In other Jasper Therapeutics news, major shareholder Velan Capital Investment Manag purchased 350,000 shares of the stock in a transaction that occurred on Thursday, February 8th. The shares were bought at an average cost of $12.95 per share, with a total value of $4,532,500.00. Following the acquisition, the insider now owns 1,188,500 shares in the company, valued at $15,391,075. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Jasper Therapeutics

Several large investors have recently modified their holdings of JSPR. Renaissance Technologies LLC grew its position in Jasper Therapeutics by 128.7% in the 4th quarter. Renaissance Technologies LLC now owns 65,400 shares of the company’s stock valued at $32,000 after acquiring an additional 36,800 shares during the last quarter. Gries Financial LLC bought a new position in Jasper Therapeutics in the 2nd quarter valued at $33,000. Ieq Capital LLC bought a new position in Jasper Therapeutics in the 4th quarter valued at $43,000. Summit Trail Advisors LLC bought a new position in Jasper Therapeutics in the 3rd quarter valued at $46,000. Finally, State Street Corp grew its position in Jasper Therapeutics by 51.2% in the 2nd quarter. State Street Corp now owns 32,884 shares of the company’s stock valued at $63,000 after acquiring an additional 11,132 shares during the last quarter. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Stock Performance

NASDAQ JSPR opened at $28.30 on Tuesday. The company has a market cap of $426.20 million, a P/E ratio of -4.56 and a beta of 2.21. The business’s 50 day moving average price is $20.82 and its 200-day moving average price is $11.92. Jasper Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $31.01.

Jasper Therapeutics (NASDAQ:JSPRGet Free Report) last released its earnings results on Monday, March 4th. The company reported ($1.50) earnings per share for the quarter, beating the consensus estimate of ($1.65) by $0.15. As a group, equities analysts predict that Jasper Therapeutics will post -5 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently commented on JSPR shares. Royal Bank of Canada started coverage on Jasper Therapeutics in a report on Thursday, March 28th. They issued an “outperform” rating and a $70.00 price target on the stock. TD Cowen began coverage on Jasper Therapeutics in a research note on Monday, March 18th. They issued an “outperform” rating on the stock. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $80.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, March 7th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $64.00.

Check Out Our Latest Analysis on JSPR

Jasper Therapeutics Company Profile

(Get Free Report)

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation.

See Also

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.